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INTRODUCTION 
Eye is that special sense of organ, which makes an indi-
vidual physically, mentally, socially and economically 
effective. Loss of function of the eye is blindness. Blind-
ness is a common and distressing complication of glau-
coma. It accounts for blindness in 5 million population 
of which 3 million is due to primary open angle glauco-
ma (POAG) throughout the world.[1] 
Primary open angle glaucoma is one such field in Oph-
thalmology where ophthalmologists have failed to stop 
blindness due to it. Despite of much experimental, clini-
cal and even speculative work, the aetiology of primary 
open angle glaucoma still remains obscure and hence, 
treatment is just empirical.[2] All the available treat-
ment modalities are directed towards the reduction of 
intraocular pressure (IOP) but without interfering the 
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basic aetiopathogenesis. Hence at the most blindness 
due to primary open angle glaucoma is delayed, but 
not eradicated in present study. As the functional dam-
age in glaucomatous eye is attributed to elevated intra-
ocular pressure, the basic aim of treating glaucoma 
whether medical, surgical or laser is to control the in-
traocular pressure.[3,4,5] Primary open angle glaucoma 
being a slowly progressive disease remains asympto-
matic in more than 50% of patients till gross diminution 
of vision or field occurs.1 In such a situation, to the 
patients laser or surgical therapy may sound high for 
the disease. This is one of the reasons for the accepta-
bility of medical therapy apart from other modalities 
being still under long term study.[5,6] Among the avail-
able drugs, there is always a constant search for the 
best in terms of efficacy, safety and economy.[7] The 
commonly used drugs in the treatment of primary open 
angle glaucoma are beta adrenergic antagonists.
[8,9,10] Beta blockers reduce the IOP by decreasing 
aqueous humor formation. The most commonly used 
drugs in this group are Timolol and Betaxalol. 
Objectives: The effectiveness of topical Timolol 0.5% 
and topical Betaxalol 0.5% in controlling raised IOP in 
POAG as well as to observe the side effects of these 
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drugs.   
In this study we proposed to study efficacy, potency 
and adverse effects of topical Timolol and Betaxalol in 
primary open angle glaucoma.  
MATERIALS AND METHODS 
Study design: An analytical observational study 
Ethics approval: Ethical clearance was taken from Insti-
tutional ethical board.  For the eligible patients, written 
informed consent was taken. 
Sample size: Fifty patients of newly diagnosed POAG 
Inclusion criteria: different age, sex, religion from both 
urban and rural population attending eye OPD patients 
with elevated IOP (IOP more than 20 mm of Hg) with or 
without glaucomatous disc or field damage with open 
anterior chamber angle were included in this study. 
Exclusion criteria: Patients with hypersensitivity to 
components of study drugs, active ocular infection or 
inflammatory disorders, history of any acute or pro-
gressive retinal disorders, use of contact lenses, history 
of previous intraocular surgery, bronchial asthma, 
chronic obstructive pulmonary disease and pregnancy 
or lactation  were excluded from the study.  
Intraocular pressure was recorded with Goldman ap-
planation tonometer under topical anaesthesia.   
Group: Total 50 patients were studied. They were di-
vided into 2 groups 
Group A: 25 patients with POAG who were treated by 
Timolol maleate 0.5%. 
Group B: 25 patients with POAG who were treated by 
Betaxalol hydrochloride 0.5%. 
Methodology: In this study a total of 50 patients with 
POAG were studied. 25 patients were treated with topi-
cal Timolol maleate 0.5% ophthalmic solution BD and 
25 patients were treated with topical 0.5% Betaxalol 
hydrochloride phthalmic solution BD. At 20 weeks fol-
low up IOP levels n both the groups measured by ap-
planation tonometer were compare to each other, 
Changes in the visual acuity, Visual field changes, optic 
disc changes and adverse effects were studied at every 
week.  Statistical analysis: Data analysis was done by 
chi square test. 
RESULTS 
Out of 50 patients, 29 (58%) were male and 21(42%) 
were female patients. POAG was most common in the 
age group of 51-60 years with mean age of 51.50 ±9.8 
S.D years. Average age in males was 54.50 years, while 
in female it was 49.31 years. (Table 1) 
In Timolol maleate group mean baseline intraocular 
pressure was 28.60 (S.D. 1.75) mm Hg. These patients 
were treated with 0.5% Timolol maleate. The mean IOP 
after 20 weeks treatment was 19.96 (S.D. 1.76) mm Hg 
and the mean reduction in IOP was 8.64 mm Hg which 
is highly significant (P<0.001). (Table 2) 
In Betaxalol hydrochloride group mean baseline intra-
ocular pressure was 27.84 (S.D. 1.61) mm Hg. These 
patients were treated with 0.5% Betaxalol hydrochlo-
ride. The mean IOP after 20 weeks treatment was 20.28 
(S.D. 1.33) mm Hg and the mean reduction in IOP was 
7.56 mm Hg which is highly significant (P<0.001). (Table 
2) 
At 20 weeks out of 25 patients receiving Timolol male-
ate 2 patients showed decrease in visual acuity by one 
Snellen’s line. In the Betaxalol hydrochloride group, 
only one patient showed decrease in visual acuity by 
one Snellen’s line.  (Table 3) 
In our study, it was very difficult to evaluate the visual 
fields in the class of patients (poor and literate) stud-
ied. Also the presence of lenticular opacities interfered 
with correct assessment of visual fields. There was no 
change in the visual fields throughout the study period 
in either group. (Table 4) In both the study groups we 
found no change in the cup disc ratio in any patients. 
(Table 5) 
Of 25 patients who received Timolol maleate, 2 pa-
tients (8%) developed mild stinging after instillation of 
the drug, while in the Betaxalol hydrochloride group 8 
patients (32%) complained of mild to moderate stinging 
for few minutes after instillation of the test drug. In 
either group discontinuation of the drug was not re-
quired. In Timolol maleate group 4 patients (16%) com-
plained of discomfort and tearing was seen in 3 pa-
tients (12%). Only one patient (4%) complained of pho-
tophobia. In Betaxalol hydrochloride group one patient 
(4%) complained of itching and 7 patients (28%) com-
plained of discomfort. (Table 6). 
Table 1. Age and sex wise distributions of 50  
patients 
 
 
Age in years Sex Total 
Male Female 
11-20 0 1 1 
21-30 0 1 1 
31-40 1 2 3 
41-50 9 4 13 
51-60 15 11 26 
61-70 4 2 6 
Total 29 21 50 
Percentage 58% 52%   
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Table 2. Distribution of mean IOP (in mm Hg)  
Table 3. Changes in the visual acuity in this study 
Table 4. Observation showing visual field changes in 
this study 
 
Table 5. Observation showing optic disc changes in 
this study 
Table 6. Ocular adverse effects in this study 
DISCUSSION 
Medical therapy is usually the first line of approach in 
POAG. The mainly used drugs in the treatment of POAG 
are beta adrenergic blockers.[3] Beta adrenergic block-
ers reduce IOP by decreasing aqueous formation.[4] In 
this study a total of 50 patients with POAG were stud-
ied. 25 patients were treated with 0.5% Timolol male-
ate ophthalmic solution and 25 patients were treated 
with 0.5% Betaxalol hydrochloride solution.  
In the follow up after 20 week, the decrease in IOP 
were highly significant (P<0.001) with Timolol. The de-
crease in IOP was 30.21%. David P. Berry et al com-
pared topical Timolol and Betaxalol in 46 patients for 
26 weeks. They found the percentage reduction of IOP 
was 33.2% in Timolol group.5 Robert H. Stewart et al, in 
their study of comparison of Timolol and Betaxalol in 
29 patients found reduction of IOP by 8.4 mm Hg 
(29%).[6,7] These results are similar to our study.  
In the follow up after 20 week, the decrease in IOP 
were highly significant (P<0.001) with betaxalol. The 
decrease in IOP was 7.56 mm Hg (27.15%). Our findings 
are nearer to previous studies by David P. Berry et al, 
who showed 28.9% reduction in IOP5 and Robert H. 
Stewart et al, who showed 7.6 mm Hg (26%) average 
reduction in Betaxalol group.[6] 
At 20 weeks out of 25 patients receiving Timolol male-
ate 2 patients showed decrease in visual acuity by one 
Observation Timolol maleate 
group 
Betaxalol hydro-
chloride group 
Baseline 28.60 27.84 
1st week 20.68 21.72 
2nd week 19.92 20.98 
4th week 19.58 20.62 
8th week 19.24 20.26 
12th week 19.92 20.62 
16th week 19.94 20.28 
20th week 19.96 20.28 
Visual acuity Timolol maleate 
group 
Betaxalol hydro-
chloride group 
On  
admis-
sion 
20th 
week 
On 
admis-
sion 
20th 
week 
6/6 2 2 3 3 
6/9 6 6 5 5 
6/12 2 2 4 4 
6/18 4 4 3 3 
6/24 3 3 2 1 
6/36 2 2 1 2 
6/60 2 2 4 4 
FC 5 meter 1 0 1 1 
FC 4 meter 0 1 1 1 
FC 3 meter 1 0 0 0 
FC 2 meter 1 1 1 1 
FC 1 meter 0 1 0 0 
PL PR (+) 1 1 0 0 
Total 25 25 25 25 
Observa-
tion 
Timolol maleate 
group 
Betaxalol hydro-
chloride group 
1st week No changes No changes 
2nd week No changes No changes 
4th week No changes No changes 
8th week No changes No changes 
12th week No changes No changes 
16th week No changes No changes 
20th week No changes No changes 
Observa-
tion 
Timolol maleate 
group 
Betaxalol hydro-
chloride group 
1st week No changes No changes 
2nd week No changes No changes 
4th week No changes No changes 
8th week No changes No changes 
12th week No changes No changes 
16th week No changes No changes 
20th week No changes No changes 
Adverse effect Timolol male-
ate group 
Betaxalol hydro-
chloride group 
Stinging or 2 8 
Discomfort 4 7 
Itching 0 1 
Tearing 3 0 
Photophobia 1 0 
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snellen’s line. In the Betaxalol group hudrochloride 
group, only one patient showed decrease in visual acui-
ty by one snellens line. Decrease in visual acuity could 
be attributed to progressive lenticular changes in all 3 
patients. Not even a single case showed sudden loss of 
vision. David P. Berry et al compared 0.5% Timolol and 
0.5% Betaxalol in 46 patients with POAG.[5] They did 
not find any visual acuity changes in both these groups. 
According to Robert H. Stewart et al no change in visual 
acuity was seen in either group in their six-month dou-
ble blind comparative study of Betaxalol and timolol 
involving 29 patients.[6] These observations are similar 
to our findings. In our study there was no change in the 
visual fields throughout the study period in either 
group.  Our findings are similar to other studies.  
In both the study groups we found no change in the 
cup disc ratio in any patients. Our findings are in ac-
cordance with the previous studies. 
CONCLUSION 
In the light of these results, we conclude that both Tim-
olol and Betaxalol are effective in decreasing IOP in 
POAG patients. The magnitude of Timolol in decreasing 
IOP is more as compared to Betaxalol. The selective 
beta 1 adrenergic inhibition of Betaxalol provides an 
added benefit for those patients in whom beta 2 block-
ade could be harmful. 
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